{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T01:08:56Z","timestamp":1793581736842,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Provectus"},{"name":"Delcath Systems"},{"name":"SWOG"},{"name":"Philogen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1245\/s10434-024-16039-5","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T16:48:20Z","timestamp":1724431700000},"page":"9150-9158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hepatic and Overall Progression-Free Survival After Percutaneous Hepatic Perfusion (PHP) as First-Line or Second-Line Therapy for Metastatic Uveal Melanoma"],"prefix":"10.1245","volume":"31","author":[{"given":"Helana","family":"Ghali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Dugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaliz","family":"Aflatooni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleena","family":"Boby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle K.","family":"DePalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Laborde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Altan F.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6886-4468","authenticated-orcid":false,"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"issue":"3","key":"16039_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/00008390-200106000-00007","volume":"11","author":"AD Singh","year":"2001","unstructured":"Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res. 2001;11(3):255\u201363. https:\/\/doi.org\/10.1097\/00008390-200106000-00007.","journal-title":"Melanoma Res."},{"issue":"5","key":"16039_CR2","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0161-6420(03)00078-2","volume":"110","author":"AD Singh","year":"2003","unstructured":"Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973\u20131997. Ophthalmology. 2003;110(5):956\u201361. https:\/\/doi.org\/10.1016\/S0161-6420(03)00078-2.","journal-title":"Ophthalmology."},{"issue":"3","key":"16039_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1023\/a:1023684502638","volume":"14","author":"PD Inskip","year":"2003","unstructured":"Inskip PD, Devesa SS, Fraumeni JF Jr. Trends in the incidence of ocular melanoma in the United States, 1974\u20131998. Cancer Causes Control. 2003;14(3):251\u20137. https:\/\/doi.org\/10.1023\/a:1023684502638.","journal-title":"Cancer Causes Control."},{"issue":"1","key":"16039_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/09286580600977281","volume":"14","author":"JM Burr","year":"2007","unstructured":"Burr JM, Mitry E, Rachet B, Coleman MP. Survival from uveal melanoma in England and Wales 1986 to 2001. Ophthalmic Epidemiol. 2007;14(1):3\u20138. https:\/\/doi.org\/10.1080\/09286580600977281.","journal-title":"Ophthalmic Epidemiol."},{"issue":"11","key":"16039_CR5","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1167\/iovs.03-0538","volume":"44","author":"E Kujala","year":"2003","unstructured":"Kujala E, M\u00e4kitie T, Kivel\u00e4 T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(11):4651\u20139. https:\/\/doi.org\/10.1167\/iovs.03-0538.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"12","key":"16039_CR6","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1200\/JCO.2004.08.194","volume":"22","author":"M Diener-West","year":"2004","unstructured":"Diener-West M, Reynolds SM, Agugliaro DJ, et al. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol. 2004;22(12):2438\u201344. https:\/\/doi.org\/10.1200\/JCO.2004.08.194.","journal-title":"J Clin Oncol."},{"key":"16039_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-023-10234-6","author":"A Huibers","year":"2023","unstructured":"Huibers A, DePalo DK, Perez MC, Zager JS, Olofsson Bagge R. Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver. Clin Exp Metastasis. 2023. https:\/\/doi.org\/10.1007\/s10585-023-10234-6.","journal-title":"Clin Exp Metastasis."},{"issue":"5","key":"16039_CR8","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/archopht.119.5.670","volume":"119","author":"Collaborative Ocular Melanoma Study Group","year":"2001","unstructured":"Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001;119(5):670\u20136. https:\/\/doi.org\/10.1001\/archopht.119.5.670.","journal-title":"Arch Ophthalmol."},{"issue":"1","key":"16039_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/01.iio.0000195852.08453.de","volume":"46","author":"AY Bedikian","year":"2006","unstructured":"Bedikian AY. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin. 2006;46(1):151\u201366. https:\/\/doi.org\/10.1097\/01.iio.0000195852.08453.de.","journal-title":"Int Ophthalmol Clin."},{"issue":"1","key":"16039_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ajo.2009.01.023","volume":"148","author":"JJ Augsburger","year":"2009","unstructured":"Augsburger JJ, Corr\u00eaa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol. 2009;148(1):119\u201327. https:\/\/doi.org\/10.1016\/j.ajo.2009.01.023.","journal-title":"Am J Ophthalmol."},{"issue":"3","key":"16039_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0161-6420(91)32285-1","volume":"98","author":"ES Gragoudas","year":"1991","unstructured":"Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patents with metastases from uveal melanoma. Ophthalmology. 1991;98(3):383\u201390. https:\/\/doi.org\/10.1016\/S0161-6420(91)32285-1.","journal-title":"Ophthalmology."},{"issue":"7","key":"16039_CR12","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1002\/1097-0142(19931001)72:7<2219::AID-CNCR2820720725>3.0.CO;2-J","volume":"72","author":"R Kath","year":"1993","unstructured":"Kath R, Hayungs J, Bornfeld N, Sauerwein W, H\u00f6ffken K, Seeber S. Prognosis and treatment of disseminated uveal melanoma. Cancer. 1993;72(7):2219\u201323.","journal-title":"Cancer."},{"issue":"12","key":"16039_CR13","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","volume":"123","author":"M Diener-West","year":"2005","unstructured":"Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005;123(12):1639\u201343. https:\/\/doi.org\/10.1001\/archopht.123.12.1639.","journal-title":"Arch Ophthalmol."},{"issue":"9","key":"16039_CR14","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1001\/jamaophthalmol.2018.2466","volume":"136","author":"AM Lane","year":"2018","unstructured":"Lane AM, Kim IK, Gragoudas ES. Survival rates in patients after treatment formetastasis from uveal melanoma. JAMA Ophthalmol. 2018;136(9):981\u20136. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.2466.","journal-title":"JAMA Ophthalmol."},{"issue":"8","key":"16039_CR15","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3109\/0284186X.2013.786839","volume":"52","author":"S Kelderman","year":"2013","unstructured":"Kelderman S, Van Der Kooij MK, Van Den Eertwegh AJM, et al. Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta Oncol. 2013;52(8):1786\u20138. https:\/\/doi.org\/10.3109\/0284186X.2013.786839.","journal-title":"Acta Oncol."},{"issue":"3","key":"16039_CR16","doi-asserted-by":"publisher","first-page":"e0118564","DOI":"10.1371\/journal.pone.0118564","volume":"10","author":"L Zimmer","year":"2015","unstructured":"Zimmer L, Vaubel J, Mohr P, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-na\u00efve patients with metastatic uveal melanoma. PLoS One. 2015;10(3):e0118564. https:\/\/doi.org\/10.1371\/journal.pone.0118564.","journal-title":"PLoS One."},{"issue":"21","key":"16039_CR17","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1002\/cncr.30258","volume":"122","author":"AP Algazi","year":"2016","unstructured":"Algazi AP, Tsai KK, Shoushtari AN, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016;122(21):3344\u201353. https:\/\/doi.org\/10.1002\/cncr.30258.","journal-title":"Cancer."},{"issue":"3","key":"16039_CR18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ejso.2016.07.145","volume":"43","author":"C Franklin","year":"2017","unstructured":"Franklin C, Livingstone E, Roesch A, Schilling B, Schadendorf D. Immunotherapy in melanoma: recent advances and future directions. Eur J Surg Oncol. 2017;43(3):604\u201311. https:\/\/doi.org\/10.1016\/j.ejso.2016.07.145.","journal-title":"Eur J Surg Oncol."},{"issue":"8","key":"16039_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12082329","volume":"12","author":"N Asher","year":"2020","unstructured":"Asher N, Ben-Betzalel G, Lev-Ari S, et al. Real world outcomes of ipilimumab and nivolumab in patients with metastatic melanoma. Cancers. 2020;12(8):1\u201318. https:\/\/doi.org\/10.3390\/cancers12082329.","journal-title":"Cancers."},{"key":"16039_CR20","first-page":"77","volume":"10","author":"RK Ausman","year":"1960","unstructured":"Ausman RK, Aust JB. Isolated perfusion of the liver with HN2. Surg Forum. 1960;10:77\u20139.","journal-title":"Surg Forum."},{"key":"16039_CR21","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.1245\/s10434-024-15293-x","volume":"31","author":"JS Zager","year":"2024","unstructured":"Zager JS, Orloff M, Ferrucci PF, et al. Efficacy and safety of the melphalan\/hepatic delivery system in patients with unresectable metastatic uveal melanoma: results from an open-label, single-arm, multicenter phase 3 study. Ann Surg Oncol. 2024;31:5340\u201351. https:\/\/doi.org\/10.1245\/s10434-024-15293-x.","journal-title":"Ann Surg Oncol."},{"key":"16039_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/1073274820983019","author":"MJ Carr","year":"2020","unstructured":"Carr MJ, Sun J, Cohen JB, et al. Over 12 years single institutional experience performing percutaneous hepatic perfusion for unresectable liver metastases. Cancer Control. 2020. https:\/\/doi.org\/10.1177\/1073274820983019.","journal-title":"Cancer Control."},{"issue":"10","key":"16039_CR23","first-page":"1758","volume":"90","author":"Y Ku","year":"1989","unstructured":"Ku Y, Saitoh M, Nishiyama H, et al. Extracorporeal adriamycin-removal following hepatic artery infusion: use of direct hemoperfusion combined with veno-venous bypass. Nihon Geka Gakkai Zasshi. 1989;90(10):1758\u201364.","journal-title":"Nihon Geka Gakkai Zasshi."},{"issue":"2","key":"16039_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/00001813-199104000-00008","volume":"2","author":"SA Curley","year":"1991","unstructured":"Curley SA, Byrd DR, Newman RA, et al. Hepatic arterial infusion chemotherapy with complete hepatic venous isolation and extracorporeal chemofiltration. Anticancer Drugs. 1991;2(2):175\u201384. https:\/\/doi.org\/10.1097\/00001813-199104000-00008.","journal-title":"Anticancer Drugs."},{"key":"16039_CR25","unstructured":"Research C for DE and FDA approves melphalan as a liver-directed treatment for uveal melanoma. FDA. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-melphalan-liver-directed-treatment-uveal-melanoma."},{"issue":"6","key":"16039_CR26","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/jso.24956","volume":"117","author":"I Karydis","year":"2018","unstructured":"Karydis I, Gangi A, Wheater MJ, et al. Percutaneous hepatic perfusion with melphalan in uveal melanoma: a safe and effective treatment modality in an orphan disease. J Surg Oncol. 2018;117(6):1170\u20138. https:\/\/doi.org\/10.1002\/jso.24956.","journal-title":"J Surg Oncol."},{"issue":"5","key":"16039_CR27","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/jso.23501","volume":"109","author":"MR Forster","year":"2014","unstructured":"Forster MR, Rashid OM, Perez MC, Choi J, Chaudhry T, Zager JS. Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience. J Surg Oncol. 2014;109(5):434\u20139. https:\/\/doi.org\/10.1002\/jso.23501.","journal-title":"J Surg Oncol."},{"issue":"4","key":"16039_CR28","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","volume":"23","author":"MS Hughes","year":"2016","unstructured":"Hughes MS, Zager J, Faries M, et al. Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases. Ann Surg Oncol. 2016;23(4):1309\u201319. https:\/\/doi.org\/10.1245\/s10434-015-4968-3.","journal-title":"Ann Surg Oncol."},{"key":"16039_CR29","doi-asserted-by":"publisher","first-page":"9510","DOI":"10.1200\/jco.2022.40.16_suppl.9510","volume":"40","author":"JS Zager","year":"2022","unstructured":"Zager JS, Orloff MM, Ferrucci PF, et al. FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301\/301A). J Clin Oncol. 2022;40:9510\u20139510. https:\/\/doi.org\/10.1200\/jco.2022.40.16_suppl.9510.","journal-title":"J Clin Oncol."},{"key":"16039_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/5672048","volume":"2020","author":"R Br\u00fcning","year":"2020","unstructured":"Br\u00fcning R, Tiede M, Schneider M, et al. Unresectable hepatic metastasis of uveal melanoma: hepatic chemosaturation with high-dose melphalan\u2014Long-term overall survival negatively correlates with tumor burden. Radiol Res Pract. 2020;2020:1\u20137. https:\/\/doi.org\/10.1155\/2020\/5672048.","journal-title":"Radiol Res Pract."},{"issue":"2","key":"16039_CR31","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1245\/s10434-020-08741-x","volume":"28","author":"TS Meijer","year":"2021","unstructured":"Meijer TS, Burgmans MC, de Leede EM, et al. Percutaneous hepatic perfusion with melphalan in patients with unresectable ocular melanoma metastases confined to the liver: a prospective phase II study. Ann Surg Oncol. 2021;28(2):1130\u201341. https:\/\/doi.org\/10.1245\/s10434-020-08741-x.","journal-title":"Ann Surg Oncol."},{"issue":"13","key":"16039_CR32","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan P, Hassel JC, Rutkowski P, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2103485.","journal-title":"N Engl J Med."},{"key":"16039_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06036-y","author":"TML Tong","year":"2022","unstructured":"Tong TML, van der Kooij MK, Speetjens FM, et al. Combining hepatic percutaneous perfusion with ipilimumab plus nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib\/randomized phase II trial. Trials. 2022. https:\/\/doi.org\/10.1186\/s13063-022-06036-y.","journal-title":"Trials."},{"issue":"9","key":"16039_CR34","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1016\/j.ejso.2021.04.038","volume":"47","author":"R Kiffin","year":"2021","unstructured":"Kiffin R, Johansson J, Olofsson Bagge R, Martner A. Anti-PD-1 checkpoint blockade improves the efficacy of a melphalan-based therapy in experimental melanoma. Eur J Surg Oncol. 2021;47(9):2460\u20134. https:\/\/doi.org\/10.1016\/j.ejso.2021.04.038.","journal-title":"Eur J Surg Oncol."},{"issue":"8","key":"16039_CR35","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1097\/COC.0000000000000356","volume":"41","author":"AM Abbott","year":"2018","unstructured":"Abbott AM, Doepker MP, Kim Y, et al. Hepatic progression-free and overall survival after regional therapy to the liver for metastatic melanoma. Am J Clin Oncol. 2018;41(8):747\u201353. https:\/\/doi.org\/10.1097\/COC.0000000000000356.","journal-title":"Am J Clin Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16039-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16039-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16039-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T13:04:20Z","timestamp":1731071060000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16039-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":35,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["16039"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16039-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"13 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Helana Ghali, Dr. Michelle M. Dugan, Shaliz Aflatooni, Aleena Boby, Dr. Danielle K. DePalo, and Dr. Jos\u00e9 Laborde report no conflicts of interest or financial ties to disclose. Dr. Jonathan S. Zager has received payments from Delcath Systems for membership on the\u00a0Medical Advisory Board. He has consulting agreements with Philogen, Merit Medical, Castle Biosciences, Replimune,\u00a0and Merck. His department receives research funding from\u00a0Philogen, SWOG, Delcath Systems, and Provectus. Dr. Junsung Choi and Dr. Altan F. Ahmed are consultants for Delcath Systems. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}